

Supplemental Table 1. Camptothecin and Indenoisoquinoline analogues.

| Camptothecins | | | | | Indenoisoquinolines | |
|----------------------------------|-------------------------------|---|----------------|----------------|-----------------------|---|
| Name | R ₁ | R ₂ | R ₃ | R ₄ | Name | R |
| Camptothecin (CPT) | H | H | H | H | NSC 706744 (Ind 1) | —CH ₂ CH ₂ CH ₂ NHCH ₂ CH ₂ OH |
| Topotecan (TPT) | H | CH ₂ NH(CH ₃) ₂ | OH | H | NSC 725776 (Ind2) | —CH ₂ CH ₂ CH ₂ N C ₂ H ₄ N |
| Irinotecan (CPT11) | C ₂ H ₅ | H | | H | NSC 724998 (Ind3) | —CH ₂ CH ₂ CH ₂ N C ₂ H ₄ N |
| SN38 | C ₂ H ₅ | H | OH | H | | |
| 9- aminocamptothecin (9AC) | H | NH ₂ | H | H | | |
| 9- nitrocamptothecin (9NC) | H | NO ₂ | H | H | | |

Supplemental Table 2. Results of correlation analysis for cell viability at GI50 for camptothecins and indenoisoquinolines

| PCC | Ind1 | Ind2 | Ind3 | 9AC | 9NC | CPT | CPT11 | SN38 | TPT |
|-------|------|------|------|-------|-------|-------|-------|-------|-------|
| Ind1 | 1 | 0.88 | 0.84 | -0.14 | -0.14 | -0.12 | -0.15 | -0.17 | -0.14 |
| Ind2 | | 1 | 0.82 | -0.11 | -0.09 | -0.10 | -0.13 | -0.14 | -0.10 |
| Ind3 | | | 1 | -0.09 | -0.05 | -0.06 | -0.11 | -0.15 | -0.10 |
| 9AC | | | | 1 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 |
| 9NC | | | | | 1 | 0.77 | 0.76 | 0.73 | 0.78 |
| CPT | | | | | | 0.94 | 0.88 | 0.86 | |
| CPT11 | | | | | | | 1 | 0.91 | 0.86 |
| SN38 | | | | | | | | 1 | 0.85 |
| TPT | | | | | | | | | 1 |

Pearson Correlation Coefficient, (PCC)